Eterna Regeneratives, a newly founded healthtech company emerging from King’s College London, has closed a $4 million seed round to advance its work on regenerative biomaterials for dental and bone repair.
The funding round was co-led by Hoxton Ventures and The Venture Collective, marking early validation for the London-based startup’s approach to addressing significant gaps in restorative medicine. Founded in 2024, Eterna Regeneratives is developing a keratin-based biomaterial platform designed to repair damaged tooth enamel and bone tissue.
Academic Origins and Innovation Focus
As a spin-out from one of the UK’s leading research institutions, Eterna Regeneratives represents the continued translation of academic research into commercial applications within the European biotech sector. The company’s foundation at King’s College London positions it within a strong research ecosystem focused on materials science and regenerative medicine.
The keratin-based biomaterial approach addresses a significant clinical need, as current treatment options for enamel and bone damage remain limited. Tooth enamel, once damaged, cannot regenerate naturally, while bone repair often requires invasive surgical interventions. The development of biological alternatives could potentially offer less invasive pathways for patients requiring these treatments.
Investor Confidence in UK Innovation
Hussein Kanji, Co-founder of Hoxton Ventures, highlighted the investment as part of a broader trend in UK innovation capability. “Regrowing teeth and bones. Once again proving that the UK can out-innovate the world!” Kanji stated, emphasizing investor confidence in the country’s ability to develop cutting-edge biomedical solutions.
Hoxton Ventures, which led the round alongside The Venture Collective, has established a track record of backing early-stage deep tech and life science companies. The $4 million seed round will support Eterna Regeneratives’ efforts to further develop its biomaterial technology and advance toward clinical applications.
Broader European Context
The funding underscores the ongoing momentum in European healthtech and biomaterials innovation. While the continent has traditionally excelled in pharmaceutical development, there has been increasing investment in regenerative medicine technologies and advanced biomaterials in recent years. UK-based startups continue to attract significant venture capital for deep science innovations, despite broader economic uncertainties.
The seed round also reflects growing investor interest in solutions addressing dental and orthopedic challenges, sectors where demand for innovative treatments remains substantial. As European healthcare systems seek cost-effective alternatives to existing procedures, companies developing regenerative approaches are attracting heightened attention from venture capital firms.
With this initial funding secured, Eterna Regeneratives enters a critical phase of technology development and validation, positioning itself within a competitive landscape of biomaterials companies working toward clinical breakthroughs in regenerative medicine.